Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
August 2017

Antidepressants and the Risk of Venous Thromboembolism
In a large study of women in England and Scotland, treatment with antidepressants was associated with an increased risk of venous thromboembolism.

Liraglutide to Combat Antipsychotic Adverse Metabolic Effects
Preliminary results suggest liraglutide (Victoza, Saxenda) may attenuate cardiometabolic risk factors in patients taking antipsychotics for the treatment of schizophrenia.

Treating Depression in Older Patients
Treating older patients with depression requires a coordinated plan with a team of professionals and should include a cognitive assessment.

In Brief
Adjunctive Riluzole (Rilutek, Teglutik) Provides No Benefit for Patients with Treatment-Resistant Major Depression; Lamotrigine (Lamictal and others) Is as Efficacious as Lithium in Postpartum Bipolar Disorder

ADHD Medication and Vehicular Crashes
Recent evidence suggests that when patients with attention-deficit/hyperactivity disorder (ADHD) take ADHD medication, it lowers their risk of motor vehicle crashes.

Valproate, Hair Loss, and Biotin
Treatment with biotin reversed hair loss induced by valproate (Depakote and others) in a woman with bipolar 1 disorder.

Antidepressants and the Risk of Venous Thromboembolism

August 2017

Venous thromboembolism (VTE), a blood clot beginning in a vein, is the third most common vascular diagnosis after myocardial infarction and stroke, and it affects about 300,000 to 600,000 Americans each year. One type of VTE is deep vein thrombosis (DVT), a clot in a deep vein, usually in the leg…

To view the rest of this article, please: